Avadel Pharma (NASDAQ: AVDL) reported Q3 EPS of $0.09, $0.11 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $39.7 million versus the consensus estimate of $37.71 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.